



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 620 276 A1**

12

## EUROPEAN PATENT APPLICATION

21 Application number: **94104042.0**

61 Int. Cl.<sup>5</sup>: **C12N 15/13, C07K 15/28,  
A61K 39/395, G01N 33/577**

22 Date of filing: **21.12.90**

This application was filed on 16 - 03 - 1994 as a  
divisional application to the application  
mentioned under INID code 60.

The applicant has subsequently filed a sequence  
listing and declared, that it includes no new  
matter.

30 Priority: **21.12.89 GB 8928874**

43 Date of publication of application:  
**19.10.94 Bulletin 94/42**

60 Publication number of the earlier application in  
accordance with Art.76 EPC: **0 460 167**

64 Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

71 Applicant: **CELLTECH LIMITED**  
**216 Bath Road**  
**Slough Berkshire SL1 4EN (GB)**

72 Inventor: **Adair, John Robert**  
**23, George Road,**  
**Stokenchurch**  
**High Wycombe, Buckinghamshire, HP14 3RN**  
**(GB)**  
Inventor: **Athwal, Diljeet Singh**  
**33 Casella Road**  
**New Cross Gate, London SE17 (GB)**  
Inventor: **Emtage, John Spencer**  
**49 Temple Mill Island**  
**Temple Marlow, Buckinghamshire, SL7 1SQ**  
**(GB)**

74 Representative: **Mercer, Christopher Paul et al**  
**Carpmaels & Ransford**  
**43, Bloomsbury Square**  
**London WC1A 2RA (GB)**

64 Humanised antibodies.

57 CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and/or (91). The CDR-grated light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non-human, e.g. rodent, donor residues and human acceptor frameworks, and may be used for *in vivo* therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.

EP 0 620 276 A1

737